bpc-157 tb-500 ghk-cu Recovery Blend - Peptides for Inflammation Support TB-500/BPC-157/GHK-Cu (10/10/50 MG) - Sigma

Lose 14-15% of your body weight* *In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise

The copper ion facilitates these reactions when energized by light photons

No medical claims are made or implied for any product and these are being sold as Nutritional/Dietary Supplements

Cardiovascular risk2.4mg/wk The dose tested in the cardiovascular outcomes trial, which cut major adverse cardiovascular events by 20% in people with established cardiovascular disease and no diabetes

Administration method: Subcutaneous injection, typically in the abdomen or thigh